Christopher Paul Walker

Part of Amgen, Inc., Amgen Research (Munich) GmbH is a biotechnology company based in Munich, Germany. The company has over 850 employees working at two locations in Germany. Amgen Scholars Europe Programs offer practical research experience to 100 students from all over Europe every summer. The company utilizes biotechnological possibilities to develop innovative treatments for diseases. The company continuously develops new substances to provide biopharmaceuticals to patients worldwide with serious illnesses. The CEOs of the company are Peter Kufer and Robert Saller. Amgen Research (Munich was acquired by ECKA Granulate GmbH & Co. KG from Aurubis AG on June 13, 2002.

AMGEN GmbH develops, manufactures, and markets human therapeutics based on cellular biology. It was established to help sell and distribute biotechnical therapies for the treatment of such ailments as chemotherapy side effects, chronic kidney failure, and rheumatoid arthritis. Among the group's products are Epogen & Aranesp for the treatment of anemia in people with chronic kidney disease; Neupogen & Neulasta to help restore white blood cell counts for cancer patients and Enbrel for the treatment of psoriasis and rheumatoid arthritis. The company was founded in 1980 and is headquartered in Munich, Germany.